Promising New Therapy for Advanced Parkinson’s Disease Enters Clinical Trials
Berlin, Germany – February 22, 2026 – In a significant step forward for the treatment of advanced Parkinson’s disease, Serina Therapeutics has announced the enrollment of the first patient in a Phase 1b registrational trial for its investigational therapy, SER-252. The trial, currently underway in Australia, aims to assess the safety, tolerability, and potential efficacy of SER-252 in individuals whose Parkinson’s symptoms are not adequately managed by existing medications. This development offers a beacon of hope for patients grappling with the debilitating motor fluctuations and side effects often associated with long-term Parkinson’s treatment.
Parkinson’s disease, a progressive neurodegenerative disorder, affects millions worldwide. Even as initial symptoms are often managed with levodopa, a medication that replenishes dopamine levels in the brain, its effectiveness diminishes over time. This leads to unpredictable “off” periods characterized by tremors, rigidity, and slow movement, alongside involuntary movements known as dyskinesia—a common side effect of prolonged levodopa use. Current continuous delivery systems, such as apomorphine infusions, attempt to mitigate these fluctuations, but often require daily injections, which can cause skin irritation and discomfort, leading to treatment discontinuation. SER-252 aims to address these challenges with a novel approach to continuous dopaminergic stimulation.
SER-252: A Novel Approach to Dopaminergic Stimulation
SER-252 is built upon the foundation of apomorphine, a potent dopamine agonist, but utilizes Serina Therapeutics’ proprietary POZ (poly(2-oxazoline)) platform. This innovative technology is designed to provide a sustained release of the medication, potentially reducing the frequency of administration and improving patient compliance. The POZ platform employs a synthetic, water-soluble polymer engineered for precise drug loading and controlled subcutaneous release, aiming to maintain stable drug levels and minimize the peaks and valleys associated with traditional therapies. According to Serina Therapeutics, this approach could significantly improve the quality of life for individuals with advanced Parkinson’s disease.
The Phase 1b trial is designed as a registrational study, meaning the data generated will be submitted to regulatory authorities, such as the U.S. Food and Drug Administration (FDA), as part of a New Drug Application (NDA). Serina Therapeutics has secured FDA alignment on its development strategy, utilizing the 505(b)(2) pathway, which can potentially expedite the review process. The company anticipates initiating patient dosing in the first quarter of 2026, consistent with previously communicated timelines. QuiverQuant reported on the initial patient enrollment on February 19, 2026.
Collaboration and Patient Recruitment
To facilitate efficient patient identification and enrollment, Serina Therapeutics is collaborating with Parkinson’s Australia and Neuroscience Trials Australia. This partnership leverages the expertise and networks of these organizations to connect with potential trial participants. Strong collaboration with local Parkinson’s specialists and advocacy groups is crucial for successful patient recruitment in clinical trials. Yahoo News highlighted the importance of these collaborations in a recent report.
The trial will assess not only the safety and tolerability of SER-252 but also its pharmacokinetic profile – how the drug is absorbed, distributed, metabolized, and excreted by the body – and preliminary efficacy signals. This comprehensive evaluation is essential for determining the potential of SER-252 as a viable treatment option for advanced Parkinson’s disease. The anticipated dosing schedule, as reported by BriefGlance, aims for once or twice weekly administration, a significant reduction compared to the daily injections required by some existing therapies.
The 505(b)(2) Pathway and Potential for Accelerated Approval
The FDA’s 505(b)(2) NDA pathway allows drug developers to rely on existing clinical data for a previously approved drug, potentially streamlining the approval process. This pathway is particularly advantageous for therapies that build upon established pharmacological principles, as is the case with SER-252 and apomorphine. Utilizing this pathway could shorten the time to market approval to between 3 and 8 years, offering a faster route for patients to access this potentially transformative treatment.
Beyond SER-252, Serina Therapeutics is actively exploring broader applications of its POZ platform. The company has entered into a non-exclusive licensing agreement with Pfizer for lipid nanoparticle drug delivery formulations, demonstrating the versatility of its technology. This suggests a potential for future innovations in drug delivery across a range of therapeutic areas.
Looking Ahead
The successful enrollment of the first patient marks a critical milestone in the development of SER-252. Serina Therapeutics plans to provide further updates as patient enrollment progresses and clinical data becomes available. The company remains focused on executing the trial and generating meaningful data to address the significant unmet medical needs of individuals living with advanced Parkinson’s disease. The next key step will be the initiation of patient dosing in the first quarter of 2026, followed by ongoing monitoring and data analysis throughout the trial period.
The development of SER-252 represents a promising avenue for improving the lives of those affected by Parkinson’s disease. As the trial progresses, the medical community and patients alike will be closely watching for results that could pave the way for a new standard of care in the management of this challenging neurological condition.
Have your say: What are your thoughts on this new approach to Parkinson’s treatment? Share your comments below, and please share this article with your network to raise awareness of this important research.